EZM 200 Pill - red round, 10mm
Generic Name: tazemetostat
Pill with imprint EZM 200 is Red, Round and has been identified as Tazverik 200 mg. It is supplied by Epizyme, Inc.
Tazverik is used in the treatment of Epithelioid Sarcoma; Follicular Lymphoma and belongs to the drug class miscellaneous antineoplastics. Tazverik 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for EZM 200
Tazverik
- Generic Name
- tazemetostat
- Imprint
- EZM 200
- Strength
- 200 mg
- Color
- Red
- Size
- 10.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Epizyme, Inc.
- National Drug Code (NDC)
- 72607-0100
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi is used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is a CAR T-cell treatment used to treat relapsed or refractory large B-cell lymphoma ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
More about Tazverik (tazemetostat)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.